BJL
ALLO icon

Brighton Jones LLC’s Allogene Therapeutics ALLO Stock Holding History

Brighton Jones LLC’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.6K Sell
33,002
-1,450
-4% -$3.18K ﹤0.01% 1340
2026
Q1 		$84.1K Buy
+34,452
New +$69.1K ﹤0.01% 1138
2025
Q4 		– Sell
-25,168
Closed -$31.2K – 90
2025
Q3 		$31.2K Buy
25,168
+11,311
+82% +$13.5K ﹤0.01% 1015
2025
Q2 		$15.7K Buy
13,857
+945
+7% +$1.26K ﹤0.01% 921
2025
Q1 		$18.9K Buy
+12,912
New +$24.3K ﹤0.01% 695

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Brighton Jones LLC's ALLO Position: Q2 2026 in Review

Brighton Jones LLC reduced its Allogene Therapeutics (ALLO) stake by 4.2% in Q2 2026, selling an estimated $3.18K and leaving 33,002 shares worth $68.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

Brighton Jones LLC first reported a position in ALLO in Q1 2025 and has held it in 5 quarters since. The position peaked at $84.1K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Brighton Jones LLC held 33,002 shares of Allogene Therapeutics worth $68.6K as of Q2 2026.
  • Brighton Jones LLC sold 1,450 Allogene Therapeutics shares in Q2 2026, an estimated $3.18K.
  • Allogene Therapeutics made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1340 holding.
  • Brighton Jones LLC first reported a position in Allogene Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Brighton Jones LLC's Allogene Therapeutics position peaked at $84.1K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.